Abbott Korea gets approval for additional indication of Humira

Abbott Korea announced Monday that they have received approval from the Korea Food and Drug Administration for treatment of moderate to severe ulcerative colitis (UC) as an additional indication of Humira (adalimumab).

The approval came after the KFDA analyzed the clinical results of adult patients who had been diagnosed with UC and had not responded well to or inadequately controlled by con...